Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.17B P/E - EPS this Y 4.90% Ern Qtrly Grth -
Income -163.43M Forward P/E -42.22 EPS next Y -53.80% 50D Avg Chg 2.00%
Sales 290.7M PEG 1.03 EPS past 5Y 21.67% 200D Avg Chg 13.00%
Dividend N/A Price/Book 0.92 EPS next 5Y -52.25% 52W High Chg -40.00%
Recommedations 2.70 Quick Ratio 4.96 Shares Outstanding 30.30M 52W Low Chg 39.00%
Insider Own 32.01% ROA -3.32% Shares Float 20.13M Beta 1.50
Inst Own 51.79% ROE -14.28% Shares Shorted/Prior 723.21K/699.33K Price 39.26
Gross Margin 39.10% Profit Margin -56.22% Avg. Volume 205,009 Target Price 27.67
Oper. Margin -26.62% Earnings Date Nov 1 Volume 194,782 Change 1.11%
About Fulgent Genetics, Inc.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Fulgent Genetics, Inc. News
12/21/24 With 54% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing
12/09/24 Wall Street Analysts Predict a 31.06% Upside in Fulgent Genetics (FLGT): Here's What You Should Know
11/22/24 All You Need to Know About Fulgent Genetics (FLGT) Rating Upgrade to Strong Buy
11/19/24 Fulgent Genetics, Inc. (FLGT): Among the Best Genomics Stocks to Buy Right Now
11/10/24 Companies Like Fulgent Genetics (NASDAQ:FLGT) Are In A Position To Invest In Growth
11/10/24 Fulgent Genetics Third Quarter 2024 Earnings: EPS Misses Expectations
11/09/24 Fulgent Genetics Reports Strong Q3 2024 Results
11/09/24 Fulgent Genetics Inc (FLGT) Q3 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Decline
11/08/24 Fulgent Genetics, Inc. (FLGT) Surpasses Q3 Earnings and Revenue Estimates
11/08/24 Fulgent Reports Third Quarter 2024 Financial Results
11/07/24 TruBridge (TBRG) Reports Q3 Loss, Tops Revenue Estimates
11/05/24 Fulgent to Participate in Upcoming Conferences
11/01/24 Fulgent Genetics (FLGT) Surges 5.8%: Is This an Indication of Further Gains?
10/31/24 Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
10/17/24 Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
10/08/24 Hims & Hers Health (HIMS) Soars 10.1%: Is Further Upside Left in the Stock?
09/18/24 Those who invested in Fulgent Genetics (NASDAQ:FLGT) five years ago are up 107%
08/13/24 Fulgent Genetics (FLGT) Upgraded to Buy: What Does It Mean for the Stock?
08/13/24 How Much Upside is Left in Fulgent Genetics (FLGT)? Wall Street Analysts Think 27.22%
08/02/24 Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
FLGT Chatroom

User Image NVDAMillionaire Posted - 4 days ago

$FLGT Fulgent Genetics (FLGT): A Diversified Genomics Leader Driving Innovation https://beyondspx.com/article/fulgent-genetics-flgt-a-diversified-genomics-leader-driving-innovation

User Image StockAutoPro Posted - 4 days ago

$FLGT: Fulgent Genetics excels in genetic testing. Buy at $18.59 target $25. Its expansion into oncology diagnostics supports future growth.

User Image StockAutoPro Posted - 6 days ago

$FLGT: Fulgent Genetics excels in genetic testing. Buy at $18.34 target $25. Its expansion into oncology diagnostics supports future growth.

User Image Sexydream Posted - 1 week ago

$FLGT glad I didn't cover. Will cover in the mid to low 18s. This gift never stops giving!

User Image Estimize Posted - 1 week ago

Wall St is expecting -0.12 EPS for $FLGT Q4 [Reporting 02/27 BMO] http://www.estimize.com/intro/flgt?chart=historical&metric_name=eps&utm_c

User Image ClarityOfPurpose Posted - 1 week ago

$FLGT Even Fartcoin has a bigger market cap than Fulgent. Yeah, that makes sense 🤣. What a messed up market. https://www.nbcnews.com/business/personal-finance/memecoins-what-are-they-why-are-they-popular-cryptocurrency-rcna184223

User Image jf152 Posted - 2 weeks ago

@ClarityOfPurpose @Sexydream Furthermore, a recession would be GREAT for $FLGT. They have no exposure to the wider economy, and investors would be forced to live in reality and invest in stocks that aren't irrationally overpriced.

User Image Sexydream Posted - 2 weeks ago

$FLGT mark this post. Next yr we will have a recession. Flgt will go as low as 10 bux a share. Don't make me say I told you so again. I told u to sell this at 60.

User Image Sexydream Posted - 2 weeks ago

$FLGT and just like that. Poof. Gonna fall below 20.

User Image Endergast07 Posted - 2 weeks ago

$FLGT Another 120K shares in after hours. Things are starting to move here...

User Image Endergast07 Posted - 2 weeks ago

$FLGT I hope @Sexydream didn't short at 17, but only starts now... Crazy thing, despite the run up it is still incredibly cheap

User Image jf152 Posted - 3 weeks ago

$FLGT

User Image CrayP Posted - 3 weeks ago

$FLGT One can debate the company's prospects but not its balance sheet. The company has $815M of cash and marketable securities ($27 per share) with negligible debt or long term or contingent liabilities. The only major use of cash (as they near positive cash flow) is to buy back stock at a major discount to cash and asset value or additional M&A. @Sexydream needs to learn how to read a balance sheet and not short stocks trading at a 30% discount to cash and 60% discount to fair value (using 3X EV/Sales). That strategy works until it doesn't but hope and spreading misinformation isn't a strategy. Of course, neither is posting arguably prejudicial memes but nobody's perfect....

User Image Sexydream Posted - 3 weeks ago

$FLGT get out while it's still 19 bux a share. Once they have to pay back all their cash this stock will go back down to $3 like pre covid days.

User Image CrayP Posted - 3 weeks ago

$FLGT I take back every bad thing I've ever said... I LOVE Ming!

User Image Bobfree Posted - 3 weeks ago

$FLGT decrashification in progress

User Image jf152 Posted - 3 weeks ago

$FLGT Volume has been heavier lately... 🤔

User Image UncleStock Posted - 3 weeks ago

$SMLR $OSUR $ELMD $FLGT suggested for Medical Equipment and Services - value screen: https://zpr.io/58kdvfpRwWhn

User Image Sexydream Posted - 3 weeks ago

$FLGT omg.... $800m cash they have. Is NOT THEIRS!!! no wonder the market values this company way below cash value. Now it makes all the sense.

User Image Estimize Posted - 3 weeks ago

Wall St is expecting -0.12 EPS for $FLGT Q4 [Reporting 02/27 BMO] http://www.estimize.com/intro/flgt?chart=historical&metric_name=eps&utm_c

User Image ClarityOfPurpose Posted - 1 month ago

$FLGT In the not too distant future, extensive biomarker identifications will likely become a key part of wellness diagnostics. Not just for cancer. Especially for people from middle age into older age. Fulgent will ride that wave.

User Image CrayP Posted - 1 month ago

$FLGT has $820M in cash trading for $550M with No Debt and $300M in b-even sales that could be sold off for 2-4X. Ming has a target on his back for any $BTC.X treasury company that wants to raid the coffers with a 50% premium for just the cash alone. $MSTR $SMLR $RIOT

User Image gatormike12 Posted - 1 month ago

$FLGT my breakeven is $74 here back from the pandemic days. I didn't sell which was a huge mistake. Is there a reason to hold this or should I take the tax loss?

User Image CrayP Posted - 1 month ago

$SMLR or $MSTR $SMRL should offer $FLGT $28 per share (a 50% premium but just cash value) in stock and then use the cash to buy more $BTC.X

User Image CrayP Posted - 1 month ago

$SMRL should offer $FLGT $28 per share (a 50% premium but just cash value) in stock and use the cash to buy more $BTC.X

User Image MustaT Posted - 1 month ago

$FLGT

User Image Ernst_Grafenberg Posted - 1 month ago

$FLGT maybe the company bought back 10% of the shares. That cash needs to be used for something. It's arguably misuse of funds at this point

User Image Ernst_Grafenberg Posted - 1 month ago

$FLGT christ, I forgot just how much this stock sucks. No reason to get battered like this while nearly every other sh*t company just soars on nothing but euphoria. There's nothing fundamental about TDOC or LMND surging by double digits daily. Extremely frustrating.

User Image Endergast07 Posted - 1 month ago

$FLGT Sexy the only one with puts:

User Image Endergast07 Posted - 1 month ago

$FLGT Institutions are accumulating

Analyst Ratings
Piper Sandler Neutral Mar 6, 24
UBS Neutral Dec 7, 23
Piper Sandler Neutral Oct 16, 23
Credit Suisse Outperform Mar 2, 23
Piper Sandler Neutral Dec 8, 22
Raymond James Outperform Nov 18, 22
Credit Suisse Outperform Nov 14, 22
Piper Sandler Overweight Nov 14, 22
Credit Suisse Outperform Aug 25, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Xie Jian President and COO President and COO Dec 11 Sell 26.5 22,000 583,000 363,124 12/13/23
Xie Jian President and COO President and COO Dec 04 Sell 27.5732 1,779 49,053 385,124 12/06/23
Kim Paul CFO and Treasurer CFO and Treasurer Dec 04 Sell 27.5732 1,437 39,623 200,460 12/06/23
Gao Hanlin Chief Scientific Off.. Chief Scientific Officer Dec 04 Sell 27.5732 1,437 39,623 905,882 12/06/23
Xie Jian President and COO President and COO Nov 16 Sell 27.2511 1,617 44,065 386,903 11/20/23
Kim Paul CFO and Treasurer CFO and Treasurer Nov 16 Sell 27.2511 1,307 35,617 201,897 11/20/23
Xie Jian President and COO President and COO Sep 07 Sell 31.4079 1,492 46,861 416,022 09/11/23
Kim Paul CFO and Treasurer CFO and Treasurer Sep 07 Sell 31.4079 1,492 46,861 214,061 09/11/23
Kim Paul CFO and Treasurer CFO and Treasurer Aug 28 Sell 33.6243 10,299 346,297 215,553 08/30/23
Xie Jian President and COO President and COO Jun 02 Sell 40.2961 1,433 57,744 425,794 06/06/23
Kim Paul CFO and Treasurer CFO and Treasurer Jun 02 Sell 40.2961 1,403 56,535 228,890 06/06/23
Gao Hanlin Chief Scientific Off.. Chief Scientific Officer Jun 02 Sell 40.2961 1,000 40,296 914,391 06/06/23
Xie Jian President and COO President and COO Nov 30 Sell 34.3932 685 23,559 430,074 12/02/22
KIM PAUL CFO and Treasurer CFO and Treasurer Sep 06 Sell 41.3942 662 27,403 149,507 09/08/22
Xie Jian President and COO President and COO Aug 30 Sell 44.183 675 29,824 309,729 09/01/22
Xie Jian President and COO President and COO Aug 17 Sell 48.8945 1,414 69,137 310,404 08/19/22
KIM PAUL CFO and Treasurer CFO and Treasurer Aug 17 Sell 48.8945 1,945 95,100 150,169 08/19/22
Gao Hanlin Chief Scientific Off.. Chief Scientific Officer Aug 17 Sell 48.8945 370 18,091 855,280 08/19/22
KIM PAUL CFO and Treasurer CFO and Treasurer Jun 02 Sell 55.102 415 22,867 153,162 06/06/22
KIM PAUL CFO and Treasurer CFO and Treasurer Mar 03 Sell 56.3081 454 25,564 155,574 03/04/22
KIM PAUL CFO and Treasurer CFO and Treasurer Nov 16 Sell 96.16 2,169 208,571 131,826 11/18/21
KIM PAUL CFO and Treasurer CFO and Treasurer Jun 04 Sell 72.8 1,250 91,000 142,188 06/04/21
KIM PAUL CFO and Treasurer CFO and Treasurer May 27 Sell 72.92 28,358 2,067,865 143,438 05/27/21
Xie Jian Chief Operating Offi.. Chief Operating Officer May 20 Sell 72.6 1,931 140,191 340,041 05/20/21